Loading clinical trials...
Loading clinical trials...
A Single-Arm Phase I/II Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT201) for The Treatment Of Advanced Solid Tumors
Conditions
Interventions
GT201
Locations
4
China
The fifth medical center of the General Hospital of the Chinese people's Liberation Army
Beijing, Beijing Municipality, China
Union Hospital Tongji Medical College Huazhong University Of Science And Technology
Wuhan, Hubei, China
Shandong Cancer Hospital
Jinan, Shandong, China
West China Hospital Sichuan University
Chengdu, Sichuan, China
Start Date
September 13, 2023
Primary Completion Date
September 13, 2026
Completion Date
September 13, 2026
Last Updated
April 27, 2026
NCT03594422
NCT06625775
NCT05223608
NCT05888532
NCT04928508
NCT06051695
Lead Sponsor
Grit Biotechnology
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions